🇰🇷South Korea·Policy·23 Jul 2026·via It비즈뉴스
AH-008 Achieves Key Clinical Milestone with Successful First Subject First Dose (FSFD) in Phase I Study for Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
TAIPEI, July 23, 2026 /PRNewswire/ -- AnHorn Medicines today announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuro...
Share this article
Original reporting by It비즈뉴스We don't republish, read the full story →
Related reading
6 stories
🇰🇷·AI News
Older Koreans Stall at Kiosks as Digital Gap Widens
🇭🇰·Policy
AI could turn China’s social credit system into surveillance tool: government-funded study
🇰🇷·AI News
Figma Bets on Design-Specific AI Agent as Quality Lags Speed
🇰🇷·AI News
Chey Tae-won Meets OpenAI's Sam Altman in Seoul to Deepen AI Alliance
🇰🇷·Startups
Samsung execs meet Open AI's Sam Altman to discuss AI transformation
🇨🇳·Policy